Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma

PURPOSE: Effective biomarkers for malignant mesothelioma (MM) are needed for clinical management and the development of mesothelin-targeted therapies. We evaluated serum megakaryocyte potentiating factor (MPF) as a biomarker predictive of treatment outcome in patients with MM and for developing meso...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCO Precis Oncol
Autori principali: Cao, Liang, Yu, Yunkai, Thomas, Anish, Zhang, Jingli, Onda, Masanori, Meltzer, Paul, Hassan, Raffit, Pastan, Ira
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
Original Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201260/
https://ncbi.nlm.nih.gov/pubmed/30370397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00282
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi